文献速递眼底病与葡萄膜炎

氟轻松丙酮化合物0.18毫克可注射玻璃体内植入剂治疗慢性葡萄膜炎的1年回顾性病例系列

A 1-Year Retrospective Case Series of Fluocinolone Acetonide 0.18-mg Injectable Intravitreal Implant in Chronic Uveitis.
PubMed 文献 · Am J Ophthalmol · 2022-10-28

该回顾性病例系列评估了新型长效氟轻松丙酮化合物0.18毫克可注射玻璃体内植入剂(FAi)在慢性葡萄膜炎中的真实世界疗效与安全性,纳入单中心103眼并随访12个月。结果显示26.1%眼最佳矫正视力提高≥2行,注射时有活动性炎症的17眼在6个月内全部消退,47.5%眼黄斑水肿消退,部分患者停用口服泼尼松或全身免疫治疗;眼压升高>10 mmHg者占6.8%,23只晶状体眼中30.4%接受白内障手术。作者认为FAi作为全身免疫抑制的辅助治疗有助于控制炎症和黄斑水肿。

要点

  • 注射时有活动性眼内炎症的17眼在6个月内炎症全部消退。
  • 47.5%眼在6个月内黄斑水肿消退,26.1%眼视力提高≥2行。
  • 6.8%眼眼压较基线升高>10 mmHg,23只晶状体眼中30.4%行白内障手术。

核心结论

  • 氟轻松丙酮化合物在我们真实世界队列中是治疗慢性葡萄膜炎的有用辅助手段。
  • FAi作为全身免疫抑制的辅助治疗,在控制活动性眼内炎症和黄斑水肿消退方面显示出获益。
  • 与既往临床试验相比,本队列激素所致眼压升高的发生率较低,白内障手术发生率与已发表文献一致。

研究设计与样本

  • 回顾性病例系列,对单中心103眼接受FAi治疗者进行病历回顾,每眼包含注射后12个月数据。
  • 结局变量由接受专科培训的葡萄膜炎专家临床定义:视力提高≥2行、眼内炎症消退、黄斑水肿消退、减少激素和免疫治疗用量、白内障手术发生率及眼压升高。

主要发现

  • 26.1%眼在12个月时视力提高≥2行。
  • 注射时有活动性眼内炎症的全部眼(n=17)在6个月时炎症消退。
  • 近半数眼在6个月时黄斑水肿消退(47.5%)。
  • 基线时口服泼尼松的患者中55%、接受全身免疫治疗的患者中35%在12个月时能够停药。
  • 6.8%眼眼压较基线升高>10 mmHg,20.4%眼在12个月时增加≥2种降眼压滴眼液;注射时23只晶状体眼中30.4%在12个月时接受白内障手术。

临床怎么用

  • 作者认为FAi可作为全身免疫抑制的辅助治疗用于慢性葡萄膜炎,有助于控制活动性眼内炎症和黄斑水肿消退。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the real-world therapeutic efficacy and safety of the novel, long-acting fluocinolone acetonide 0.18-mg injectable intravitreal implant (FAi) in chronic uveitis. DESIGN: Retrospective case series. METHODS: A retrospective chart review was performed on 103 eyes treated with FAi at a single academic uveitis center including 12 months of postinjection data for each eye. Outcome variables were clinician-defined by fellowship-trained uveitis specialists: ≥2-line visual acuity (VA) improvement, resolution of intraocular inflammation, resolution of macular edema, corticosteroid- and immunotherapy-sparing effect, incidence of cataract surgery, and intraocular pressure (IOP) rise. RESULTS: 26.1% of eyes had ≥2-line VA improvement by 12 months. All eyes with active intraocular inflammation at injection (n=17) had resolution of activity by month 6. Nearly half of eyes had resolution of macular edema by month 6 (47.5%). Fifty-five percent of patients on oral prednisone and 35% of patients on systemic immunotherapy at baseline were able to discontinue the therapy by month 12. In addition, 6.8% of eyes had IOP rise >10 mm Hg from baseline and 20.4% had ≥2 IOP drops added by month 12. Among the 23 phakic eyes at injection, 30.4% underwent cataract surgery by month 12. CONCLUSION: Fluocinolone acetonide was a helpful adjunct for the treatment of chronic uveitis in our real-world cohort. Specifically, FAi showed benefit in the control of active intraocular inflammation and resolution of macular edema when used as an adjunct to systemic immunosuppression. Our cohort had lower rates of steroid-induced increase in IOP as compared to prior clinical trials and incidence of cataract surgery consistent with those published in the literature.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Andrews H, Nair A, Hamdan S, et al. A 1-Year Retrospective Case Series of Fluocinolone Acetonide 0.18-mg Injectable Intravitreal Implant in Chronic Uveitis. Am J Ophthalmol. 2022. PMID: 39110158. doi:10.1016/j.ajo.2022.10.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。